PTEN and neoplasm: By contrast, all but one of five AZD8931-treated MMTV-NIC PTEN+/− tumours became rapidly insensitive to AZD8931, and by day 40 all AZD8931-treated tumours had grown beyond their initial starting volume, with a median percentage change in tumour volume of 131.1%.